Intranet PAC-CI
Terminé

A Phase III, randomized, open-label, multicenter trial evaluating the non-inferiority of raltegravir compared with efavirenz, in combination with tenofovir and lamivudine, in antiretroviral-naive individuals infected with HIV-1 receiving rifampin for active tuberculosis.

A Phase III, randomized, open-label, multicenter trial evaluating the non-inferiority of raltegravir compared with efavirenz, in combination with tenofovir and lamivudine, in antiretroviral-naive individuals infected with HIV-1 receiving rifampin for active tuberculosis.

Project Details

Description & Context

A Phase III, randomized, open-label, multicenter trial evaluating the non-inferiority of raltegravir compared with efavirenz, in combination with tenofovir and lamivudine, in antiretroviral-naive individuals infected with HIV-1 receiving rifampin for active tuberculosis.

Research Team

The research team has not yet been filled in for this project.

Collaborate with us

We are open to partnerships with international research institutions and doctoral students.

Research Request

Estimated response time: 3-5 business days.

Keywords

OUR PROJECTS
Exploration

Discover other projects

Tous les projets